Overview

Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
Phase:
Phase 3
Details
Lead Sponsor:
Shenyang Sunshine Pharmaceutical Co., LTD.